What a HUGE call. Many congrats to you! 89bio shares are trading higher after the company's Phase 2b ENLIVEN trial of pegozafermin in NASH achieved statistical significance on both primary histology endpoints. by Bill Haddad, Benzinga Editor March 22, 2023 7:49 AM | 18 seconds read
Market Data 
Markets 
AI
